荷兰孕中期母亲破伤风、白喉和无细胞百日咳疫苗接种的反应原性与安全性
荷兰自2019年12月起为所有孕妇在孕中期提供Tdap疫苗接种。本研究纳入2019年8月至2021年12月孕20-24周接种Tdap的孕妇,评估反应原性并与孕30-33周接种的历史数据比较,同时将不良妊娠结局与2018年国家数据比较。结果显示孕中期接种安全且耐受良好,与孕晚期接种相比无反应原性差异,不良妊娠结局未增加。
要点
- 723名完成问卷的参与者中,67.5%出现至少一种局部反应,63.6%出现至少一种全身不良事件。
- 孕20-24周与孕30-33周接种Tdap后不良事件无差异。
- 723名接种者与2,424名未接种孕妇匹配,早产、小于胎龄儿等不良妊娠结局未增加。
核心结论
- 孕中期母亲Tdap疫苗接种似乎安全且耐受良好。
- 孕中期与孕晚期接种比较未发现反应原性方面的担忧。
研究设计与样本
- 孕妇于2019年8月至2021年12月纳入,在孕20至24周接种Tdap疫苗。
- 参与者完成接种后一周内局部反应和全身不良事件问卷。
- 反应原性结果与孕30至33周接种的历史数据(n=58)比较。
- 安全性结局方面,每名参与者按居住地区、产次和年龄与荷兰围产期登记处四名未接种孕妇匹配。
主要发现
- 723名完成问卷的参与者中,488名(67.5%)经历至少一种局部反应,最常见为注射部位疼痛(62.3%)。
- 460名(63.6%)经历至少一种全身不良事件,最常见为肌肉/关节僵硬(38.9%)、疲劳(28.9%)、头痛(14.5%)和感冒样症状(11.0%)。
- 4名女性(0.6%)报告发热(≥38.0˚C)。
- 症状被认为轻微且数日内短暂。
- 孕20-24周与孕30-33周接种后不良事件无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maternal tetanus-diphtheria-and-acellular-pertussis (Tdap) vaccination is offered to all pregnant women during their second trimester in the Netherlands since December 2019. We assessed second trimester Tdap vaccination reactogenicity and compared with third trimester data from a similar study. For safety assessment, adverse pregnancy outcomes were compared with national data from 2018, before Tdap vaccine-introduction. METHODS: Pregnant women were included between August 2019-December 2021 and received Tdap vaccination between 20 and 24w gestational age (GA). Participants completed a questionnaire on solicited local reactions and systemic adverse events (AEs) within one week after vaccination. Results were compared with historical data on reactogenicity from women vaccinated between 30 and 33w GA (n = 58). Regarding safety-related outcomes, each participant was matched to four unvaccinated pregnant women from the Dutch Perinatal Registry, based on living area, parity and age. RESULTS: Among 723 participants who completed the questionnaire, 488 (67.5 %) experienced ≥ 1 local reaction with pain at the injection site as most reported reaction (62.3 %), and 460 (63.6 %) experienced ≥ 1 systemic AE with stiffness in muscles/joints (38.9 %), fatigue (28.9 %), headache (14.5 %) and common cold-like symptoms (11.0 %) most frequently reported. 4 women (0.6 %) reported fever (≥38.0˚C). Symptoms were considered mild and transient within days. No difference in AEs were found between vaccination at 20-24w versus 30-33w GA. 723 participants were matched to 2,424 unvaccinated pregnant women with no increased rates of premature labor, small-for-gestational-age, or other adverse pregnancy outcomes. CONCLUSIONS: Second trimester maternal Tdap vaccination appears safe and well-tolerated. Comparison between second versus third trimester vaccination yielded no reactogenicity concerns.
引用
- Immink MM, Kemmeren JM, Broeders L, et al. Reactogenicity and safety of second trimester maternal tetanus, diphtheria and acellular pertussis vaccination in the Netherlands. Vaccine. 2023. PMID: 36604217. doi:10.1016/j.vaccine.2022.12.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。